UK drugmaker sues Teva over patent challenge

November 9, 2005 13:56
1 minute read.


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Drugmaker AstraZeneca PLC said Wednesday that it has filed a lawsuit in a US court against Teva Pharmaceutical Industries Ltd. over a patent challenge to one of its key drugs from its Israeli rival. The Anglo-Swedish company said it had begun action in US District Court in New Jersey against Teva for "willful infringement" of the substance patent that protects its best-selling schizophrenia treatment Seroquel. The lawsuit is a response to an application filed by Teva in late September with the US Food and Drug Administration to market a generic version of a 25 milligram tablet version of the drug in the United States before AstraZeneca's patent expires in 2011. "AstraZeneca has full confidence in and will continue vigorously to defend and enforce its intellectual property rights protecting Seroquel," the company said in a statement to the London Stock Exchange.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection


Cookie Settings